 disease.[unreadable] [unreadable] Chaperone Therapy: We have identified a number of patients with Fabry disease in whom the reduced catalytic activity of alpha-galactosidase A is increased in the presence of the molecular chaperone 1-deoxy-galactonojirimycin (DGJ). This technique is based
disease.[unreadable ] [ unreadable ] Chaperone Therapy: We have identified a number of patients with Fabry disease in whom the dilute catalytic natural process of alpha - galactosidase A is increased in the presence of the molecular chaperone 1 - deoxy - galactonojirimycin (DGJ). This proficiency is based
 didease.[unreadable] [unreadabue] Chaperone Thgrqpy: We have jdentifidd a number of patients with Fqbry eisease in whom the reauced catwlytic axtivmty of alpha-galarfosidasc A ia incxeesed in the prexence of tve molecular cvaoexone 1-deoxy-galactonojirimycin (DGJ). Thif technoqke is based
disease.[unreadable] [unreadable] Chaperone Therapy: We have identified of with Fabry in whom the A increased in the of the molecular 1-deoxy-galactonojirimycin (DGJ). This technique is based
 disease.[unreadable] [unreadabLe] ChaperonE TherApy: we hAvE ideNtifIed a number of paTIentS with Fabry disease in whoM the rEdUCed cATaLytic ActivitY Of ALPha-GaLaCtoSiDAsE A is iNcrEased in The presencE of ThE molecular chAPeRone 1-deoxy-gAlaCtonojirimycIn (DgJ). This TeChnIQue is BasEd
 disease.[unreadable] [unr eadable] C haper one  Th er apy:  Wehave identifie d  a n umber of patients with  Fabr yd isea s ein wh om ther ed u c edca ta lyt ic ac tivit y o f alpha -galactosi das eA is increas e din the pre sen ce of the mo lec ular c ha per o ne 1- deo xy-ga lacton o jirimy cin (DGJ) .T his te c hniquei s  b ased 
 disease.[unreadable]_[unreadable] Chaperone_Therapy: We have identified_a number_of_patients with_Fabry_disease in whom_the reduced catalytic_activity of alpha-galactosidase A_is increased in_the_presence of the molecular chaperone 1-deoxy-galactonojirimycin (DGJ). This technique is based